Neoadjuvant Therapy

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

2 weeks ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

1 year ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery

1 year ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Immunologic Adjuvants, Malignant neoplasm of lung, Neoadjuvant Therapy, Non-Small Cell Lung Carcinoma, Surgery specialty, United States Food and Drug Administration

FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC